Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/bioAffinity Technologies, Inc./ 8-K

Current Report · Items 8.01, 9.01 · 8-K

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Other Events

Item 8.01. Other Events. On September 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath® Lung, in clinical practice and ongoing research evaluating the technology in veteran and military populations at the 2026 NAVREF Annual Conference, September 27-30, 20…

Filed Sep 22, 2026Accepted Sep 22, 2026, 8:30 AM EDTCIK 1712762Accession 0001493152-26-043654
View company →Permanent SEC source ↗
Share

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

BIAFNASDAQ · EQUITY · CurrentBIAFWNASDAQ · WARRANT · Current

Recent company filings

  1. Other EventsSep 17, 2026
  2. Regulation FD DisclosureSep 11, 2026
  3. Other EventsSep 9, 2026
  4. 424B3 filingSep 8, 2026
  5. EFFECT filingSep 4, 2026

Registered securities in this filing

bioAffinity Technologies, Inc. · 8-K · Filed 2026-09-22

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.007 per share

Symbol
BIAF
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-09-222026-09-22_custom_CommonStockParValue0.007PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants to purchase Common Stock

Symbol
BIAFW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: From2026-09-222026-09-22_custom_WarrantsToPurchaseCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226043654 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. On September 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath® Lung, in clinical practice and ongoing research evaluating the technology in veteran and military populations at the 2026 NAVREF Annual Conference, September 27-30, 2026, in Arlington, Virginia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans SAN ANTONIO, Texas - September 22, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath® Lung, in clinical practice and ongoing research evaluating the technology in veteran and military populations at the 2026 NAVREF Annual Conference, September 27-30, 2026, in Arlington, Virginia. The National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference brings together leaders from the Department of Veterans Affairs (VA), VA-affiliated research organizations, academia and industry working to improve healthcare and quality of life for veterans. bioAffinity Technologies is a member of NAVREF’s Industry P…

Open exhibit ↗